Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.52 |
| ▸ | TYK2 | P29597 | 8/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | TNNI3K | Q59H18 | 5/20 | 0.41 |
| ▸ | SYK | P43405 | 2/20 | 0.41 |
| ▸ | GCK | P35557 | 2/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247520 | 0.84 | GRM5 (0.54) | GRM5TYK2TNNI3KGCKEGFR | |
| SCHEMBL31247640 | 0.81 | TYK2 (0.41) | TYK2LMNAARTNNI3KGCK | |
| SCHEMBL31247458 | 0.79 | GCK (0.46) | TYK2LMNAARTNNI3KGCK | |
| SCHEMBL25242188 | 0.76 | TYK2 (0.45) | GRM5TYK2TNNI3K | |
| SCHEMBL31247372 | 0.76 | CDK1 (0.46) | TYK2LMNAARTNNI3KGCK | |
| SCHEMBL31300245 | 0.76 | CDK1 (0.46) | TYK2LMNAARTNNI3KGCK | |
| SCHEMBL31247474 | 0.75 | TYK2 (0.43) | TYK2LMNAARTNNI3KGCK | |
| SCHEMBL31247362 | 0.74 | TYK2 (0.41) | TYK2LMNAARTNNI3KGCK | |
| SCHEMBL31247547 | 0.74 | BRAF (0.40) | TYK2LMNAARTNNI3KGCK | |
| SCHEMBL15533542 | 0.73 | GRM5 (0.49) | GRM5EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719394-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ATOMWISE INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20240425484-A1 | INHIBITORS OF TYK2 | Atomwise Inc. | 2024-12-26 | — | — | US | disclosed |
| WO-2024250010-A2 | INHIBITORS OF TYK2 | Atomwise Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048051-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | TYK2, FRK, DYRK2 | GRM5 1437/4885TYK2 1/4885LMNA 3034/4885 |
| US-20240425484-A1 | INHIBITORS OF TYK2 | TYK2, LCK, JAK2 | GRM5 2396/4885TYK2 1/4885LMNA 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.